New DIA Asia Conference
DIA has held the DIA Asia New Drug Conference over 12 years in Japan, but this time, with the introduction of the new ICH framework, we will start a new conference series called “DIA Asia International Conference”. It has been decided to hold it under the cooperation of the various Asian countries; the first one is to be held in Tokyo and future ones will be held in other Asian counties in turn. In this conference, we will provide not only a program suitable for the new ICH scheme, but also a useful information exchange forum for the drug development in the new ara. New regulatory trends in various Asian countries will also be shared and provide an opportunity to discuss how counties in Asia can collaborate and provide breakthrough solutions for the patients.
Asia, the most important emerging region in the world
Asia has a huge population that accounts for 60% of the world, and economic growth is prominent, attracting global attention. Many countries has characteristic aging populations, and the increased medical needs have become similar to other developped regions. Asian countries are similar in many ways, such as culture, behavioral/language characteristics, ethnic factors, etc. In order to discuss common issues under such circumstances, forum where Asian people get together to share opinions would be very useful. On the other hand, the proportion of new products derived from Asia among medicines around the world, is still small, and the proportion of Asians in the clinical trials conducted worldwide is small, so that the Asia is expected to play a more important role in the global drug development in the future.
Asia, the future, changing with ICH
This year, the ICH has determined to allow multiple Asian regulators to join ICH as official members, drastically changing from 3 originating regions of the US, EU and Japan. These countries are all moving to a new era when they can introduce common pharmaceutical regulations and discuss issues on the same foundation. To meet the unmet medical needs, regulators are trying to accelerate the drug development, including the introduction of an expedited review process. Asian academies/companies also change the methods using a various new technologies to find a solution. It is becoming necessary to pay an effort to understand both the cutting-edge science and technology and changes in medical needs, flexibly responding to patient expectations.
We will be expecting your active participation!
Day 1: ICH Day
Day 2: Asia Conference Day
Who should attend?
The program will benefit those with the following interests:
• Clinical development • Medical affairs and market • Regulatory affairs
• Academic organizations • Clinical study sites • Regulatory agencies
• CROs and SMOs
Shinobu Uzu, MSc • Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Ari Fujishiro • Senior Director, Regulatory Affairs Group, Asia Development Dept., R&D Division
Daiichi Sankyo Co., Ltd., Japan
Shunsuke Izuka • Manager, Japan-Asia Clinical Development 1
Astellas Pharma Inc., Japan
In-Jin Jang, MD, PhD •
Seoul National University College of Medicine, Korea, Republic of
Kosuke Mitsui, MBA, MSc, PMP • Senior Director, Clinical Research Department
Chugai Pharma Science (Beijing) Co., Ltd., China
Atsushi Nonogaki, MSc • Manager, Regulatory Affairs Group, Asia Development Department, R&D Division
Daiichi Sankyo Co., Ltd., Japan
Junko Sato •
Chugai Pharmaceutical Co., Ltd., Japan
Jin Shun, MBA • Head, Regulatory Affairs, APAC
Ling Su, PhD • Past President, DIA Board of Directors; Professor
Shenyang Pharmaceutical University, China
Crystal Wang • Director of Development Division
Chugai Pharma Taiwan Ltd., Taiwan